Nebido

 

ISMH Men's Health

Conferences

Access recorded conference sections presented by local and international experts

Bayer logo Bayer logo Bayer logo Bayer logo

The role of TRT in the management of hypogonadism

Description

In his presentation “The role of TRT in the management of hypogonadism: Dispelling the myths”, Dr. Geoffrey Hackett looks at safety concerns in connection with testosterone replacement therapy (TRT).

Effects of TRT on various parameters of cardiometabolic health are shown, and current evidence regarding prostate safety is presented.

 

Speakers

Professor Geoff Hackett

Professor Geoff Hackett
Aston University &
University Hospitals Birmingham NHS Foundation Trust

Alt tag

Related Videos

Related Videos

ISMH introduction

ISMH introduction

Professor Ridwan Shabsigh

Read more

The epidemiology and burden of hypogonadism

The epidemiology and burden of hypogonadism

Professor Siegfried Meryn

Read more

The clinical picture of hypogonadism

The clinical picture of hypogonadism

Professor Myles Spar

Read more

To screen or not to screen

To screen or not to screen

Professor Siegfried Meryn

Read more

The evidence for testosterone replacement therapy (TRT)

The evidence for testosterone replacement therapy (TRT)

Professor Ridwan Shabsigh

Read more

Who do I treat when, how and with what?

Who do I treat when, how and with what?

Professor Joel Heidelbaugh

Read more

Copyright © 2021, Bayer AG

This website contains information on Nebido® (testosterone undecanoate) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.

 

This website is intended to provide information to an international audience outside Austria, France, Germany, Hungary, Ireland, the Middle East, the Philippines, Thailand, the UK, and the USA.

Page last modified 01/04/2021

PP-NEB-ALL-0222-1 April 2021

  • PP-NEB-ALL-0222-1 April 2021

BayerBayer